-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Does China Pioneer Pharma Holdings (HKG:1345) Deserve A Spot On Your Watchlist?
Does China Pioneer Pharma Holdings (HKG:1345) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.
Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like China Pioneer Pharma Holdings (HKG:1345). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing.
View our latest analysis for China Pioneer Pharma Holdings
How Fast Is China Pioneer Pharma Holdings Growing?
The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. That makes EPS growth an attractive quality for any company. To the delight of shareholders, China Pioneer Pharma Holdings has achieved impressive annual EPS growth of 48%, compound, over the last three years. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. While revenue is looking a bit flat, the good news is EBIT margins improved by 4.4 percentage points to 14%, in the last twelve months. That's something to smile about.
You can take a look at the company's revenue and earnings growth trend, in the chart below. To see the actual numbers, click on the chart.
SEHK:1345 Earnings and Revenue History September 9th 2022While profitability drives the upside, prudent investors always check the balance sheet, too.
Are China Pioneer Pharma Holdings Insiders Aligned With All Shareholders?
Prior to investment, it's always a good idea to check that the management team is paid reasonably. Pay levels around or below the median, can be a sign that shareholder interests are well considered. The median total compensation for CEOs of companies similar in size to China Pioneer Pharma Holdings, with market caps between CN¥1.4b and CN¥5.6b, is around CN¥2.9m.
China Pioneer Pharma Holdings' CEO took home a total compensation package of CN¥556k in the year prior to December 2021. First impressions seem to indicate a compensation policy that is favourable to shareholders. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of a culture of integrity, in a broader sense.
Does China Pioneer Pharma Holdings Deserve A Spot On Your Watchlist?
China Pioneer Pharma Holdings' earnings per share have been soaring, with growth rates sky high. With increasing profits, its seems likely the business has a rosy future; and it may have hit an inflection point. What's more, the fact that the CEO's compensation is quite reasonable is a sign that the company is conscious of excessive spending. It will definitely require further research to be sure, but it does seem that China Pioneer Pharma Holdings has the hallmarks of a quality business; and that would make it well worth watching. We should say that we've discovered 2 warning signs for China Pioneer Pharma Holdings (1 is significant!) that you should be aware of before investing here.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於許多投資者,尤其是那些缺乏經驗的投資者來説,購買有好故事的公司的股票是很常見的,即使這些公司在虧損。但現實是,當一家公司每年虧損時,在足夠長的時間內,投資者通常會承擔他們的損失份額。虧損的公司可能會像海綿一樣吸收資本,因此投資者應該謹慎,不要把錢一筆接一筆地往上扔。
儘管處於科技股藍天投資的時代,許多投資者仍採取更傳統的策略;購買盈利的公司的股票,如中國先鋒醫藥控股有限公司(HKG:1345)。雖然這並不一定意味着它是否被低估了,但該業務的盈利能力足以證明它有一定的升值價值--特別是如果它在增長的話。
查看我們對中國先鋒醫藥控股的最新分析
中國先鋒醫藥控股的增長速度有多快?
市場在短期內是一臺投票機,但從長期來看是一臺稱重機,所以你可以預期股價最終會跟隨每股收益(EPS)的結果。這使得每股收益的增長對任何公司來説都是一個有吸引力的品質。令股東高興的是,中國先鋒醫藥控股有限公司在過去三年中取得了令人印象深刻的每股收益年複合增長率48%。這麼快的增長可能是轉瞬即逝的,但它應該足以激起警惕的選股者的興趣。
營收增長是一個很好的指標,表明增長是可持續的,再加上高息税前利潤(EBIT)利潤率,這是一家公司在市場上保持競爭優勢的絕佳方式。雖然收入看起來有點持平,但好消息是,在過去12個月中,息税前利潤增長了4.4個百分點,達到14%。這是一件值得微笑的事情。
你可以在下面的圖表中看到該公司的收入和收益增長趨勢。要查看實際數字,請點擊圖表。
聯交所:1345盈利及收入歷史2022年9月9日雖然盈利能力推動了上行,但謹慎的投資者總是會檢查資產負債表。
中國先鋒醫藥控股的內部人士是否與所有股東一致?
在投資之前,檢查管理團隊的薪酬是否合理總是一個好主意。薪酬水平接近或低於中位數,可能是股東利益得到充分考慮的跡象。與中國先鋒醫藥股份有限公司(China Pioneer Pharma Holdings)規模類似、市值在14億加元至56億加元之間的公司首席執行官的總薪酬中值約為290萬加元。
在2021年12月之前的一年裏,中國先鋒醫藥控股公司的首席執行官拿到了總計55.6萬元的薪酬。第一印象似乎表明了一種有利於股東的薪酬政策。CEO薪酬水平不是投資者最重要的衡量標準,但當薪酬適中時,這確實有助於加強CEO與普通股東之間的一致性。在更廣泛的意義上,它也可以是一種誠信文化的標誌。
中國先鋒醫藥控股值得登上你的觀察名單嗎?
中國先鋒醫藥控股公司的每股收益一直在飆升,增長率達到了極高的水平。隨着利潤的增加,這項業務似乎有一個美好的未來;它可能已經遇到了一個轉折點。更重要的是,CEO的薪酬相當合理,這表明該公司意識到了過度支出。這肯定需要進一步的研究才能確定,但中國先鋒醫藥控股公司似乎確實具備高質量業務的特徵;這將使其非常值得關注。我們應該説我們已經發現了中國先鋒醫藥控股公司的2個警告信號(1很重要!)在這裏投資之前你應該意識到這一點。
總是有可能做得很好,購買股票不是不斷增長的收入和不要有內部人士購買股票。但對於那些考慮這些重要指標的人,我們建議您查看以下公司做擁有這些功能。你可以在這裏訪問它們的免費列表。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧